Last reviewed · How we verify

Phylloquinone

Guy's and St Thomas' NHS Foundation Trust · Phase 2 active Small molecule Under review

Phylloquinone is a Small molecule drug developed by Guy's and St Thomas' NHS Foundation Trust. It is currently in Phase 2 development for Antibiotic-Induced Hypoprothrombinemia, Anticoagulant-Induced Prothrombin Deficiency, Factor II deficiency. Also known as: Vitamin K1.

Phylloquinone, also known as vitamin K1, is a small molecule vitamin found in food and on the World Health Organization's List of Essential Medicines. It is used as a dietary supplement and has been studied in clinical trials for conditions such as intracranial hemorrhages and subarachnoid hemorrhage, often in conjunction with anticoagulant medications like apixaban and rivaroxaban.

Likelihood of approval
13.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Cardiovascular Phase 3 risk -2.0pp
    Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePhylloquinone
Also known asVitamin K1
SponsorGuy's and St Thomas' NHS Foundation Trust
TargetAlpha-synuclein
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 2

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Phylloquinone

What is Phylloquinone?

Phylloquinone is a Small molecule drug developed by Guy's and St Thomas' NHS Foundation Trust, indicated for Antibiotic-Induced Hypoprothrombinemia, Anticoagulant-Induced Prothrombin Deficiency, Factor II deficiency.

What is Phylloquinone used for?

Phylloquinone is indicated for Antibiotic-Induced Hypoprothrombinemia, Anticoagulant-Induced Prothrombin Deficiency, Factor II deficiency, Hypocalcemia, Neonatal Hemorrhagic Disease.

Who makes Phylloquinone?

Phylloquinone is developed by Guy's and St Thomas' NHS Foundation Trust (see full Guy's and St Thomas' NHS Foundation Trust pipeline at /company/guy-s-and-st-thomas-nhs-foundation-trust).

Is Phylloquinone also known as anything else?

Phylloquinone is also known as Vitamin K1.

What development phase is Phylloquinone in?

Phylloquinone is in Phase 2.

What does Phylloquinone target?

Phylloquinone targets Alpha-synuclein.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing